Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Due Diligence
Comparison
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
PR Newswire

MS Society Comments on Social Care Consultation

— LONDON, May 12

LONDON, May 12 /PRNewswire/ -- Welcoming the launch of the consultation on social care reform, Simon Gillespie, chief executive of the MS Society, said: "We're acutely aware that most people with MS feel the social care system is failing them. The criteria for access to funding are too tight - the funding shortfall isn't 20 years away, it's with us right now.

"This consultation is a once in a generation opportunity for the government to fix social care. We need to make sure the young and disabled aren't left out because current provision for them is pitiful."

Background

There are 85,000 people with MS in the UK. Most are diagnosed in their 20s and 30s and it affects three times as many women as men. Symptoms include loss of sight and mobility, grinding fatigue, chronic nerve pain, depression, sexual dysfunction and incontinence. MS is incurable and there are few effective treatments.

Related news

Partnering consultation free of charge
Bioiberica
Need competitive intelligence information
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us